Çelik, FatmanurTan, Yusuf ZiyaÖzdemir, SemraSılan, Fatma2025-01-272025-01-2720192146-1414https://doi.org/10.4274/mirt.galenos.2019.60352https://search.trdizin.gov.tr/tr/yayin/detay/368591https://hdl.handle.net/20.500.12428/13417Objectives: The aim of this study was to compare the quantitative value of standardized uptake value (SUV) SUVmax obtained from F-18 FDG positron emission tomography/computed tomography (PET/CT) imaging of oncology patients with the cell-free DNA (cfDNA) amounts measured in plasma of patients and thus investigate if cfDNA is a significant marker to identify the presence of malignancy in the early period. Methods: A total of 184 patients were included in the study. The clinical, histopathologic, laboratory and treatment parameters were extracted from patient files. SUVmax and cfDNA quantities were assessed. Results: There was no statistically significant difference in plasma cfDNA values between patient and control groups. The comparison of SUVmax and cfDNA values in the study showed that there was a weak correlation between SUVmax and cfDNA. There was a significant difference between tumor size and SUVmax values. However, there was no statistically significant difference between tumor size and cfDNA. Conclusion: cfDNA measurements in the blood as a screening test have provided hope for early diagnosis and monitoring of cancer patients. Comparison of cfDNA levels obtained from plasma and quantitative parameters from PET/CT images of oncology patients in detailed advanced studies with larger patient series are required. © 2019 by Turkish Society of Nuclear Medicine Molecular Imaging and Radionuclide Therapy published by Galenos Yayınevi.eninfo:eu-repo/semantics/openAccessCell-free DNA; F-18 FDG PET/CT; SUV_maxArticle282465210.4274/mirt.galenos.2019.603522-s2.0-85071149367368591Q3